Affordable Access

deepdyve-link
Publisher Website

MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.

Authors
  • Si, Pilei1
  • Shi, Jinjin2
  • Zhang, Pei3
  • Wang, Cao4
  • Chen, Haijun4
  • Mi, Xuefang4
  • Chu, Wenling4
  • Zhai, Baoping1
  • Li, Wentao5
  • 1 Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Henan University People's Hospital, Zhengzhou, 450003, China. , (China)
  • 2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. , (China)
  • 3 Henan Provincial Food and Drug Evaluation and Inspection Center, Henan Food and Drug Administration, Zhengzhou, 450008, China. , (China)
  • 4 Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China. , (China)
  • 5 Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Henan University People's Hospital, Zhengzhou, 450003, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Cancer letters
Publication Date
Mar 01, 2020
Volume
472
Pages
165–174
Identifiers
DOI: 10.1016/j.canlet.2019.12.019
PMID: 31857156
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application. Copyright © 2019 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times